Dainippon Dips Into Unknown iPS-Drug Sector By Partnering With Startups
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma may have positioned itself to become one of the first pharmaceutical companies out of the chute in the rapidly expanding regenerative medicine business based on induced pluripotent stem cells.